Results 11 to 20 of about 100,711 (219)
Patient Outcomes Among Medicare Beneficiaries With Guillain-Barré Syndrome. [PDF]
J Peripher Nerv SystABSTRACT Background and Aims Understanding of population‐level outcomes for patients with Guillain–Barré syndrome (GBS) remains limited. We identified which GBS patients are most likely to experience worse outcomes using the largest and most current GBS cohort in the United States.
Wright B +5 more
europepmc +2 more sources
Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine
Cureus, 2021 Since the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China, in December 2019, Coronavirus - 19 (COVID-19) has become a global pandemic with multiple neurological complications.
S. Waheed +4 more
semanticscholar +1 more source
Triggers of Guillain–Barré Syndrome: Campylobacter jejuni Predominates
International Journal of Molecular Sciences, 2022 Guillain–Barré syndrome (GBS) is a rare immune-mediated acute polyradiculo-neuropathy that typically develops after a previous gastrointestinal or respiratory infection. This narrative overview aims to summarise and discuss current knowledge and previous
J. Finsterer
semanticscholar +1 more source
Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States
JAMA Network Open, 2023 This cohort study investigates the association of Ad26.COV2.S, BNT162b2, and mRNA-1273 COVID-19 vaccination with rates of Guillain-Barré syndrome among US adults.
W. Abara +12 more
semanticscholar +1 more source
Guillain–Barré Syndrome Associated with SARS-CoV-2
New England Journal of Medicine, 2020 Guillain–Barre Syndrome with Covid-19 Five patients who had Guillain–Barre syndrome 5 to 10 days after the onset of Covid-19 are described.
G. Toscano +11 more
semanticscholar +1 more source
Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 Vaccination
Annals of Neurology, 2021 Although SARS‐CoV‐2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain–Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford–AstraZeneca SARS‐CoV‐2 vaccine.
C. Allen +6 more
semanticscholar +1 more source
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink
JAMA Network Open, 2022 Key Points Question Are COVID-19 vaccines associated with Guillain-Barré syndrome (GBS)? Findings In this cohort study of surveillance data from the Vaccine Safety Datalink that included 15.1 million doses of COVID-19 vaccines, the unadjusted incidence ...
K. Hanson +13 more
semanticscholar +1 more source
European Journal of Neurology, 2021 Mounting evidence supports an association between Guillain−Barré syndrome spectrum (GBSs) and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection.
L. Palaiodimou +13 more
semanticscholar +1 more source
Journal of Neurology, 2020 Since coronavirus disease-2019 (COVID-19) outbreak in January 2020, several pieces of evidence suggested an association between the spectrum of Guillain–Barré syndrome (GBS) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Samir Abu-Rumeileh +4 more
semanticscholar +1 more source
Journal of the American Medical Association (JAMA), 2021 Importance As part of postauthorization safety surveillance, the US Food and Drug Administration (FDA) has identified a potential safety concern for Guillain-Barré syndrome (GBS) following receipt of the Ad26.COV2.S (Janssen/Johnson & Johnson) COVID-19 ...
E. Woo +5 more
semanticscholar +1 more source